Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

Rhea-AI Summary

Aurora (NASDAQ: ACB) is expanding its medical cannabis portfolio in Australia and New Zealand, launching multiple THC flower products in New Zealand and four resin cartridges in Australia on Feb 11, 2026. Products use Aurora proprietary genetics and are manufactured at EU‑GMP and TGA‑GMP certified facilities in Canada.

The New Zealand roll‑out includes Big Wave, Night Ride, and Half Moon (Q1 FY27). Australia debuts Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze, reinforcing the company’s regional growth focus.

Key Figures

Big Wave THC: 26% THC Big Wave CBD: <1% CBD Night Ride THC: 29% THC +5 more

8 metrics

Big Wave THC 26% THC New Zealand Big Wave™ hybrid flower

Big Wave CBD <1% CBD New Zealand Big Wave™ hybrid flower

Night Ride THC 29% THC New Zealand Night Ride™ indica flower

Night Ride CBD <1% CBD New Zealand Night Ride™ indica flower

Half Moon THC 9% THC New Zealand Half Moon™ hybrid flower

Half Moon CBD 13% CBD New Zealand Half Moon™ hybrid flower

Resin THC 780 mg/g THC Australian resin cartridges (multiple strains)

Resin CBD <10 mg/g CBD Australian resin cartridges (multiple strains)

Market Reality Check

Price: $3.56 Vol: Volume 1,130,449 vs 20-da...

normal vol

$3.56 Last Close

Volume Volume 1,130,449 vs 20-day average 1,251,404 shares, indicating typical trading activity pre-announcement. normal

Technical Shares at 3.56 are trading below the 200-day MA of 4.82, reflecting a pre-existing downtrend before this news.

Peers on Argus

Ahead of this positive international expansion news, ACB was down 0.84% while pe...

Ahead of this positive international expansion news, ACB was down 0.84% while peers like OGI (-12.58%), IRWD (-5.17%), TKNO (-3.24%), LFCR (-1.47%) and SXTC (-2.67%) were also lower, suggesting broader weakness but no momentum-flagged sector move.

Historical Context

5 past events · Latest: Feb 04 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	ATM equity program	Negative	-7.6%	Announced prospectus supplement for up to U.S.$100M at-the-market offering.
Feb 04	Earnings results	Positive	-7.6%	Reported Q3 FY2026 growth, positive EBITDA and reaffirmed full-year guidance.
Feb 03	Digital expansion	Positive	+3.6%	Launched localized European medical websites and central auroramedicine.com hub.
Jan 21	Earnings call notice	Neutral	+2.1%	Scheduled Q3 2026 results release and investor conference call details.
Jan 20	IP protection	Positive	-2.1%	Secured EU Community Plant Variety Rights for two proprietary cultivars.

Pattern Detected

Recent history shows mixed reactions: positive strategic and IP updates sometimes met with declines, while web expansion and scheduling news drew modest gains, and an ATM filing aligned with a notable selloff.

Recent Company History

Over the past few weeks, Aurora reported Q3 FY2026 results with total net revenue of $94.2M and record global medical cannabis revenue of $76.2M, yet the stock fell 7.64%. An at-the-market equity program for up to U.S.$100M similarly coincided with a 7.64% decline. In contrast, launching localized European medical websites produced a 3.57% gain, while securing EU Community Plant Variety Rights for proprietary cultivars saw a 2.13% drop. Today’s Australia/New Zealand portfolio expansion continues the theme of global medical growth alongside volatile price responses.

Market Pulse Summary

This announcement expands Aurora’s medical portfolio in Australia and New Zealand with new THC flowe...

Analysis

This announcement expands Aurora’s medical portfolio in Australia and New Zealand with new THC flower strains at 26% and 29%, a balanced option with 9% THC and 13% CBD, and resin cartridges containing 780 mg/g THC. It reinforces the company’s long-term global medical focus and follows recent European digital initiatives and IP wins. Observers may watch how these launches contribute to medical revenue and product mix over time.

Key Terms

cbd, eu-gmp, tga-gmp, hybrid, +2 more

6 terms

cbd medical

"Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%"

Cannabidiol (CBD) is a natural compound found in hemp and cannabis plants that does not produce the “high” associated with THC. Investors care because CBD is sold in a wide range of consumer products and medical treatments, so changes in regulation, clinical evidence, or consumer demand can quickly affect company sales, margins and legal risk — think of it as a product line whose value depends on shifting rules and public trust.

eu-gmp regulatory

"manufactured at the company's leading EU-GMP and TGA-GMP certified facilities"

EU‑GMP is a regulatory standard that certifies pharmaceutical and related manufacturing facilities in the European Union meet strict quality and safety rules for producing medicines and medical products. For investors, an EU‑GMP certificate is like a trusted food‑safety rating for a factory: it signals lower regulatory and supply risk, access to EU markets, and greater confidence that products are consistently made to required specifications.

tga-gmp regulatory

"manufactured at the company's leading EU-GMP and TGA-GMP certified facilities"

An TGA-GMP certificate means a drug or medical device maker meets Australia’s Therapeutic Goods Administration standards for how products are manufactured, stored and quality-checked. For investors, it’s like a regulatory “health inspection” pass for a factory: it lowers the chance of product recalls or supply disruptions, enables lawful sales in Australia (and can support approvals elsewhere), and therefore reduces regulatory and commercial risk for a company.

hybrid medical

"Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%"

A hybrid is a combination of two different things designed to work together, often to improve performance or offer new benefits. For investors, it can mean an asset or strategy that blends features from different types of investments, aiming to reduce risk or increase potential returns. This mix helps create a balanced approach, offering both stability and growth opportunities.

indica medical

"Night Ride™ – Flower, Indica, THC 29%, CBD <1%"

Cannabis indica is one of the primary types of cannabis plants, typically shorter and bushier with broad leaves, and is commonly associated with calming or sedating effects because of its typical mix of chemical compounds. For investors, indica matters because it helps define product categories, consumer demand, cultivation costs and facility needs — like choosing between dark-roast and light-roast coffee varieties, different plant types can command different prices, margins and retail positions.

sativa medical

"Soul Train Haze™ – Resin Cartridge, Sativa, THC 780mg/g, CBD <10mg/g"

Sativa is a group of cannabis plants and product types commonly associated with energizing, wakeful effects versus the more sedating varieties; it’s often used on labels to signal how a cannabis product might make a user feel. For investors, sativa matters because it helps determine product positioning, consumer demand, regulatory labeling and pricing—think of it like choosing a bold coffee roast that targets a morning crowd rather than an evening decaf.

AI-generated analysis. Not financial advice.

NASDAQ | TSX: ACB

Launch reinforces Aurora's leadership position across key international markets 

EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora^® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

The expansion in New Zealand this month includes two new THC flower products – Big Wave™, Night Ride ™, as well as the balanced strain, Half Moon™ coming soon in Q1 FY27. The brand will also debut four new resin cartridges in Australia this month including, Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™.

"With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region," says Stanley Sack, Interim Managing Director of MedReleaf Australia. "As patient needs evolve, so does our responsibility to deliver high‑quality, diversified product formats that support prescribers in delivering better care. Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on."

Each new product is derived from Aurora's proprietary genetics, and manufactured at the company's leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety.

New Zealand Launches:

• Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%
• Night Ride™ – Flower, Indica, THC 29%, CBD <1%
• Half Moon™ – Flower, Hybrid, THC 9%, CBD 13%

Australia Launches:

• Chemango™ Kush – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
• Cosmic Cream™ – Resin Cartridge, Indica, THC 780 mg/g, CBD <10mg/g
• Lunar Express™ - Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
• Soul Train Haze™ – Resin Cartridge, Sativa, THC 780mg/g, CBD <10mg/g

Aurora remains a trusted choice for prescribers and patients around the globe. With a broad portfolio of high-quality medical cannabis, proven regulatory expertise, and strong leadership across a dozen markets, Aurora continues to raise the bar for supporting patient care.

 About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora^®, MedReleaf^®, Pedanios^®, IndiMed^™, San Raf^®, Tasty's^® and Whistler Medical Marijuana Co.^®. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis^™.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's portfolio expansion in Australia and New Zealand and benefits for patients, the Company's commitment to continued investment in those markets, and the Company's strategic focus on long-term global growth.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-advances-global-medical-growth-strategy-with-portfolio-expansion-in-australia--new-zealand-302684262.html

SOURCE Aurora Cannabis Inc.

FAQ

What products did Aurora (ACB) launch in New Zealand on Feb 11, 2026?

Aurora launched two THC flower products and announced a balanced strain coming in Q1 FY27. According to Aurora, New Zealand launches include Big Wave (THC 26%), Night Ride (THC 29%), and Half Moon (THC 9%, CBD 13%).

Which Aurora (ACB) resin cartridges debuted in Australia and what are their THC levels?

Aurora introduced four resin cartridges in Australia this month with high THC concentration. According to Aurora, Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze each contain 780 mg/g THC with CBD below 10 mg/g.

Where are Aurora (ACB) medical products manufactured and what quality standards apply?

Aurora manufactures these products in Canada under recognized GMP standards. According to Aurora, the products are produced at facilities certified to EU‑GMP and TGA‑GMP, intended to ensure consistent quality and safety for prescribers and patients.

How does Aurora (ACB) describe its strategic focus for Australia and New Zealand?

Aurora says Australia and New Zealand are top regional priorities with ongoing investment to expand access. According to Aurora, the expansion aims to deliver diversified product formats, reliable supply, and enhanced choice for patients and prescribers.

What are the expected near‑term product availability timelines for Aurora (ACB) in the region?

Most new products are launching this month, with one balanced strain scheduled for early next fiscal year. According to Aurora, Big Wave and Night Ride plus four cartridges launch immediately, while Half Moon is expected in Q1 FY27.